MENU
+Compare
HEPA
Stock ticker: NASDAQ
AS OF
Dec 20 closing price
Price
$0.49
Change
-$0.04 (-7.55%)
Capitalization
3.42M

HEPA Hepion Pharmaceuticals Forecast, Technical & Fundamental Analysis

a pharmaceutical company, which engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease

Industry Biotechnology
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for HEPA with price predictions
Dec 20, 2024

Momentum Indicator for HEPA turns negative, indicating new downward trend

HEPA saw its Momentum Indicator move below the 0 level on December 02, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned negative. In of the 86 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for HEPA turned negative on November 27, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .

HEPA moved below its 50-day moving average on December 02, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HEPA crossed bearishly below the 50-day moving average on December 04, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HEPA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for HEPA entered a downward trend on December 20, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HEPA advanced for three days, in of 221 cases, the price rose further within the following month. The odds of a continued upward trend are .

HEPA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.112) is normal, around the industry mean (14.556). P/E Ratio (0.000) is within average values for comparable stocks, (87.563). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.739). HEPA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (256.215).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. HEPA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HEPA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

HEPA is expected to report earnings to rise 61.11% to -290 cents per share on May 16

Hepion Pharmaceuticals HEPA Stock Earnings Reports
Q1'23
Est.
$-2.90
Q4'22
Missed
by $1.68
Q3'22
Beat
by $0.06
Q2'22
Missed
by $4.94
Q1'22
Est.
$-0.09
The last earnings report on March 01 showed earnings per share of -179 cents, missing the estimate of -11 cents. With 48.09K shares outstanding, the current market capitalization sits at 3.42M.
A.I. Advisor
published General Information

General Information

a pharmaceutical company, which engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
399 Thornall Street
Phone
+1 732 902-4000
Employees
25
Web
https://www.hepionpharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LWLG1.960.13
+7.10%
Lightwave Logic
ABOS1.850.05
+2.78%
Acumen Pharmaceuticals
CUBE42.660.92
+2.20%
CubeSmart
LAUR18.360.18
+0.99%
Laureate Education
ASNS1.030.01
+0.98%
Actelis Networks

HEPA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HEPA has been loosely correlated with AVIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HEPA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HEPA
1D Price
Change %
HEPA100%
-7.37%
AVIR - HEPA
45%
Loosely correlated
+1.92%
PMCB - HEPA
39%
Loosely correlated
N/A
TNFA - HEPA
34%
Loosely correlated
-7.48%
OTLK - HEPA
34%
Loosely correlated
+3.60%
ATAI - HEPA
34%
Loosely correlated
N/A
More